Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2639)	2/6/2019 10:25:39 AM
From: Miljenko Zuanic	Read Replies (1) of 3557

4Q report.....Eylea ex-US sale were $724.4 m, which is better than my estimate. Again, for 2018 20%y/y growth in ex-US. Show what true partners means when MARKETING is main reason. I am projecting further capture and expansion of the market, which now stand at 58% for ex-US. Contrary, Sonofi continue to BULSHIT with Dupi/Pra/Kew ex-US sale. Libtayo 4Q sale are more or less OK!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next